Several parameters are used to predict the theragnostic and orientation of treatment (efficacity of TMZ) of patients with glioblastoma, including epigenetic modification of the O6-methylguanine-DNA methyltransferase (MGMT) gene [6]. The gene discussed is MGMT; the disease is glioblastoma.